• LinkedIn
  • Facebook
  • Welcome
  • Company
  • Technology
  • Investors
  • News
  • Contact Us
  • Fighting COVID-19
News & Events      All / Archive
Clear Filters
Categories
Clear Filters Press Releases Technology Events Other

01-08-2021

Bold Therapeutics Secures Funding to Prepare BOLD-100 for COVID-19 Clinical Trials


01-06-2021

Bold Therapeutics Collaborators at University of Vienna Published Study Detailing the Binding Partners and Mechanism of Action of BOLD-100


12-18-2020

Bold Therapeutics COVID-19 Program Chosen by National Research Council of Canada for Development Support


10-09-2020

Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100


09-17-2020

BOLD-100 Shows Inhibition of DNA Repair Pathways in Breast Cancer


08-17-2020

BOLD-100 Significantly Outperforms Remdesivir Head-to-Head in SARS-CoV-2 (COVID-19) Model


07-15-2020

BOLD-100 Demonstrates Nanomolar Range Inhibition of Live COVID-19 In Vitro


06-11-2020

 Bold Therapeutics Expands COVID-19 Consortium 


05-28-2020

Bold Therapeutics and Hana Pharm Execute Option Agreement for Exclusive Development and Commercialization Rights to BOLD-100 in South Korea


04-15-2020

Bold Therapeutics and the University of Ottawa Initiate Research Partnership to Study BOLD-100 in the Treatment of COVID-19


03-27-2020

Bold Therapeutics Seeks Collaborators for Rapid Development of BOLD-100; Lead Drug Candidate Has Potential Utility in the Treatment of COVID-19


03-27-2020

Bold Therapeutics to Initiate Phase 1b Trial of BOLD-100 in GI Cancers


02-10-2020

Bold Therapeutics Visiting Collaborators in Europe


View All

Bold Therapeutics Logo

  • Welcome
  • Company
  • Careers
  • Technology
  • Investors
  • News
  • Contact Us
  • Dashboard

© Copyright Bold Therapeutics. All rights reserved.
Powered by PounceTek